Literature DB >> 2017258

Processing of the precursor of NF-kappa B by the HIV-1 protease during acute infection.

Y Rivière1, V Blank, P Kourilsky, A Israël.   

Abstract

Transcription of the human immunodeficiency virus type-1 (HIV-1) genome is regulated in part by cellular factors and is stimulated by activation of latently infected T cells. T-cell activation also correlates with the induction of the factor NF-kappa B which binds to two adjacent sites in the HIV-1 long terminal repeat. This factor consists of two DNA-binding subunits of relative molecular mass 50,000 (50K) associated with two 65K subunits. It is located in the nucleus in mature B cells, but is present in other cell types as an inactive cytoplasmic complex. External stimuli, including those that activate T cells, result in nuclear translocation of active NF-kappa B. The cloning of the complementary DNA for the 50K subunit helped to identify an exclusively cytoplasmic 105K precursor (p105) (V.B., P.K. and A.I., manuscript submitted). The expression of active NF-kappa B might therefore also be regulated by the extent of processing of p105. Because HIV-1 requires active NF-kappa B for efficient transcription, we tested the effect of HIV-1 infection on the processing of the human 105K precursor. We show here that the HIV-1 protease can process p105 and increases levels of active nuclear NF-kappa B complex.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2017258     DOI: 10.1038/350625a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  61 in total

1.  Toxins that are activated by HIV type-1 protease through removal of a signal for degradation by the N-end-rule pathway.

Authors:  P O Falnes; R Welker; H G Kräusslich; S Olsnes
Journal:  Biochem J       Date:  1999-10-01       Impact factor: 3.857

2.  Reversible oxidative modification as a mechanism for regulating retroviral protease dimerization and activation.

Authors:  David A Davis; Cara A Brown; Fonda M Newcomb; Emily S Boja; Henry M Fales; Joshua Kaufman; Stephen J Stahl; Paul Wingfield; Robert Yarchoan
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

3.  Epstein-Barr virus latent membrane protein transactivates the human immunodeficiency virus type 1 long terminal repeat through induction of NF-kappa B activity.

Authors:  M L Hammarskjöld; M C Simurda
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

Review 4.  Translation initiation of the HIV-1 mRNA.

Authors:  Théophile Ohlmann; Chloé Mengardi; Marcelo López-Lastra
Journal:  Translation (Austin)       Date:  2014-10-31

5.  The C terminus of the NF-kappa B p50 precursor and an I kappa B isoform contain transcription activation domains.

Authors:  P J Morin; T D Gilmore
Journal:  Nucleic Acids Res       Date:  1992-05-25       Impact factor: 16.971

6.  An active-site mutation in the human immunodeficiency virus type 1 proteinase (PR) causes reduced PR activity and loss of PR-mediated cytotoxicity without apparent effect on virus maturation and infectivity.

Authors:  J Konvalinka; M A Litterst; R Welker; H Kottler; F Rippmann; A M Heuser; H G Kräusslich
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

7.  Identification of structural mechanisms of HIV-1 protease specificity using computational peptide docking: implications for drug resistance.

Authors:  Sidhartha Chaudhury; Jeffrey J Gray
Journal:  Structure       Date:  2009-12-09       Impact factor: 5.006

8.  T cell activation and disease severity in HIV infection.

Authors:  M Mahalingam; M Peakman; E T Davies; A Pozniak; T J McManus; D Vergani
Journal:  Clin Exp Immunol       Date:  1993-09       Impact factor: 4.330

9.  Moloney murine leukemia virus activates NF-kappa B.

Authors:  J Pak; D V Faller
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

10.  BCL3 encodes a nuclear protein which can alter the subcellular location of NF-kappa B proteins.

Authors:  Q Zhang; J A Didonato; M Karin; T W McKeithan
Journal:  Mol Cell Biol       Date:  1994-06       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.